bpsc-1001 vaccine

Vaccineexperimental

Clinical trial activity

7 trials · 10 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
3
Phase 3
1
Phase 4
0

Earliest trial started Oct 1, 2014 (NCT02269423)

Timeline

2010s

  1. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2015

    Earliest Phase 3 Sponsor(trial)

  3. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • EbolavirusImmunity, active

    Ebolavirus immunity, active

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • bpsc-1001 vaccine
  • v920

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05130398Phase 1/Phase 2 (Phase 2)Apr 9, 2021Centre de Recherche Médicale de Lambaréné, Merck
NCT03031912Phase 2Jun 30, 2017Canadian Immunization Research Network, Dalhousie University, Merck
NCT02503202Phase 3Aug 17, 2015Merck
NCT02314923Phase 1Dec 1, 2014BioProtection Systems Corporation, Department of Health and Human Services, Merck
NCT02374385Phase 1Nov 1, 2014Canadian Institutes of Health Research (CIHR), Dalhousie University, NewLink Genetics Inc
NCT02269423Phase 1Oct 1, 2014BioProtection Systems Corporation, Department of Defense, Merck
NCT02280408Phase 1Oct 1, 2014BioProtection Systems Corporation, Merck, National Institute of Allergy and Infectious Diseases (NIAID)
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (10)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MerckFor profit6432014
BioProtection Systems CorporationFor profit3012014
Dalhousie UniversityAcademic/Hospital2222014
Canadian Immunization Research NetworkAcademic/Hospital1012017
Canadian Institutes of Health Research (CIHR)Academic/Hospital1012014
Centre de Recherche Médicale de LambarénéAcademic/Hospital1112021
Department of DefenseGovernment1012014
Department of Health and Human ServicesGovernment1012014
National Institute of Allergy and Infectious Diseases (NIAID)Government1012014
NewLink Genetics IncFor profit1012014
10 organizations
Page 1 / 1